Cite
HARVARD Citation
Papp, K. et al. (n.d.). A phase 2a randomized, double‐blind, placebo‐controlled, sequential dose‐escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate‐to‐severe psoriasis. British journal of dermatology. pp. 767-776. [Online].